Recent Updates
Recently added Catalysts

Herpes simplex virus containing gD-Alum

Phase 1

Prophylaxis Herpes Simplex | Monoclonal antibody | Infectious Disease |GSK plc|Last Updated: Jun 17, 2008

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedCONTROLLED
Total Trials1
Total Enrollment130

FDA Designations

No designations recorded

Clinical trial landscape

Herpes simplex virus containing gD-Alum · 1 trial · 1 indication

Phase 1 1
NCT00698490Humoral and Cellular Immune Response of Herpes Simplex (gD) Candidate Vaccines From 2 Different Cell LinesProphylaxis Herpes Simplex
COMPLETED130 Analytics
PHASE1COMPLETED
Humoral and Cellular Immune Response of Herpes Simplex (gD) Candidate Vaccines From 2 Different Cell Lines
Prophylaxis Herpes Simplex
NCT00698490130
Unlock trial analytics

Study Endpoints

Primary Endpoints

To evaluate in initially HSV-seronegative subjects the GMT's and the seroconversion rates of anti-gD2 antibodies (ELISA)
After the second and third doses of each vaccine
To evaluate in initially HSV-seronegative subjects, the GMT and the seropositivity rate of anti-HSV-2 neutralizing antibodies
To evaluate the cell-mediated immune (CMI) response (lymphoproliferation, secretion of interleukin 2 and γ interferon)
After the second and third dose of each vaccine formulation
To evaluate, in initially seronegative subjects and in initially seropositive subjects, the incidence and intensity of solicited local and general signs and symptoms
During 3 days after each dose of each vaccine
To evaluate in initially seropositive subjects, the GMT and the seropositivity rate of anti-gD2 antibodies (ELISA) and of anti-HSV-2 neutralizing antibodies
After 2 and 3 doses of vaccines
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposePREVENTION

Treatment Arms

ArmTypeDescription
Group AEXPERIMENTALHSV-seronegative subjects
Group BEXPERIMENTALHSV-seropositive subjects
Group CEXPERIMENTALHSV-seronegative subjects
Group DEXPERIMENTALHSV-seronegative subjects
Group EEXPERIMENTALHSV-seronegative subjects

Interventions

NameTypeDescription
Adjuvanted herpes simplex (gD) candidate vaccine GSK 208141BIOLOGICALIntramuscular injection, 3 doses, 2 different formulations
Herpes simplex virus containing gD-AlumBIOLOGICALIntramuscular injection, 3 doses
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 45 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Between 18 and 45 years of age * Written informed consent * Female volunteers must be using contraception and should avoid becoming pregnant for the duration of the vaccination course * Serology: Groups 1, 3, 4 and 5: HSV-1 AND HSV-2 seronegative (by gD2 ELISA); Group 2: HSV s...

Countries:Belgium
Unlock Eligibility Criteria

Frequently asked questions about Herpes simplex virus containing gD-Alum

What is Herpes simplex virus containing gD-Alum used for?

Herpes simplex virus containing gD-Alum is an investigational vaccine being developed for prophylaxis of herpes simplex. It is designed to prevent herpes simplex virus infection, and it is currently in Phase 1 clinical development. The vaccine is being studied in healthy volunteers to evaluate its safety and immunogenicity.

Who makes Herpes simplex virus containing gD-Alum?

Herpes simplex virus containing gD-Alum is being developed by GSK plc, a global biopharma company listed on the stock exchange under the ticker GSK. GSK is conducting clinical trials to evaluate the vaccine's potential for prophylaxis of herpes simplex.

What phase is Herpes simplex virus containing gD-Alum in?

Herpes simplex virus containing gD-Alum is in Phase 1 clinical development. It is an investigational vaccine, meaning it has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the vaccine is still in the early stages of clinical testing.

What clinical trials is Herpes simplex virus containing gD-Alum in?

Herpes simplex virus containing gD-Alum has one completed Phase 1 clinical trial, identified as NCT00698490. The trial, titled 'Humoral and Cellular Immune Response of Herpes Simplex (gD) Candidate Vaccines From 2 Different Cell Lines,' enrolled 130 participants in Belgium and evaluated the vaccine in healthy volunteers.

Is Herpes simplex virus containing gD-Alum the same as a herpes vaccine?

Herpes simplex virus containing gD-Alum is a candidate vaccine for prophylaxis of herpes simplex. It is designed to elicit an immune response against the herpes simplex virus. The vaccine is currently in Phase 1 clinical development, and its efficacy in preventing herpes simplex has not yet been established.